In the MTX and sTNFi (ETN) group, CRP levels at LPD onset were higher than those in the MTX monotherapy group, and the rates of HL-like lesions, MALToma, and primary submandibular lesions increased. The gene discussed is CRP; the disease is disseminated peritoneal leiomyomatosis.